Trump to Sign Executive Order Targeting Prescription Drug Prices On May 12, 2025, U.S. President Donald Trump announced plans to sign an executive order aimed at significantly reducing the cost of prescription medications for Americans. In a statement shared on Truth Social, Trump indicated that the measure would align U.S. drug prices with those paid …
Continue reading “Trump’s Executive Order Aims to Cut Prescription Drug Prices for Americans”
These Cannabis-Sector Stocks Aren’t Typical Yield Plays: Why They’re Worth the Risk The cannabis industry is often viewed through the lens of its playful products with unique names such as “Khalifa Kush” or “Zen Leaf.” However, beyond the whimsy, there’s a financially compelling aspect for yield-seeking investors: attractive dividends offered by cannabis-sector lenders. As traditional …
WeightWatchers Files for Bankruptcy Amid Debt Crisis WeightWatchers, now known as WW International Inc., has filed for bankruptcy, a significant development that highlights the ongoing struggles of the health and wellness giant. The company’s decision comes on the heels of its attempt to diversify its services by incorporating GLP-1 weight-loss treatments, yet the results were …
Novo Nordisk Shares Rise Despite Reduced Earnings Outlook In a surprising turn of events that reflects the challenging landscape faced by pharmaceutical companies, shares of Novo Nordisk (Nasdaq: NVO) surged 3% in early Copenhagen trading on May 7, 2025, despite the company announcing a cut to its earnings expectations for the year. The Danish pharmaceutical …
Continue reading “Novo Nordisk Stock Surges 3% Despite Earnings Cut and Market Challenges”
US Net Drug Spending Surged 11.4% Last Year, Boosted by Obesity and Oncology Meds: IQVIA As predictable as the dawn, prescription medicine use and overall drug spending continue to escalate in the United States. The IQVIA Institute, a prominent life sciences intelligence firm, recently released a comprehensive report examining trends in medicine usage backed by …
Continue reading “US Drug Spending Skyrockets 11.4% Driven by Obesity and Oncology Medications”
OpenAI Transitions to Public-Benefit Corporation Amid Growing Demand for AI OpenAI, the prominent artificial intelligence startup, recently announced a significant shift in its corporate structure as it grapples with the burgeoning demand for its AI services. A letter from CEO Sam Altman revealed that the company will abandon its previous plans to transition into a …
Biopharma Leaders Push Back Against Tariffs Amid U.S. Manufacturing Expansion As leading pharmaceutical companies aim to expand their U.S. operations with substantial investments, a notable number of biopharma executives are voicing their opposition to the current tariff policies enforced by the Trump administration. They argue that tax reform is a more effective means to support …
Continue reading “Biopharma CEOs Urge Tax Reform Over Tariffs to Fuel U.S. Manufacturing Growth”
$880 Billion in Medicaid Cuts: A Threat to Nursing Homes and Vulnerable Populations As the nursing-home industry finds itself caught amidst a contentious congressional budget debate, proposed reductions of at least $880 billion in mandatory spending cuts to Medicaid could spell disaster for nursing homes and their residents. Medicaid, a federal-state partnership program, plays a …
GE Healthcare Projects $500 Million Tariff Impact in 2025 GE Healthcare Technologies Inc., a prominent player in the medical technology sector, has revealed that it anticipates absorbing around $500 million in tariff-related costs by 2025, predominantly influenced by ongoing bilateral tariffs between the United States and China. The announcement came during the company’s quarterly earnings …
Pfizer Maintains 2025 Profit Outlook Despite Paxlovid’s Sales Decline On April 30, 2025, Pfizer Inc., a dominant player in the pharmaceutical industry, reaffirmed its profit forecast for 2025, even as it contended with a significant drop in sales of its COVID-19 therapeutic, Paxlovid. This announcement came as the company reported a revenue miss in its …
Continue reading “Pfizer Reaffirms 2025 Profit Forecast Amid 75% Decline in Paxlovid Sales”
